# Tesamorelin + Ipamorelin

> A GH-secretagogue pairing built on an FDA-approved GHRH analog (Tesamorelin) plus a selective secretagogue (Ipamorelin).

- Also known as: Tesamorelin/Ipamorelin, Tesa Ipa
- Class: Growth Hormone
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/tesamorelin-ipamorelin

## Overview

A combination of Tesamorelin — a stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy — with Ipamorelin, a selective ghrelin-receptor secretagogue. It applies the same two-receptor logic as the CJC-1295 + Ipamorelin pairing, but uses a GHRH analog that has cleared clinical trials and carries an approved indication. The blend itself is a research combination: Tesamorelin is approved as a single agent, not in combination with Ipamorelin, and the mixture has no dedicated trial.

This pairing is the “clinical-grade GHRH” version of the GHRH-plus-secretagogue stack. Tesamorelin is a GHRH analog with real trial data and an FDA approval for reducing visceral fat in HIV lipodystrophy; Ipamorelin adds a selective ghrelin-receptor signal on top. The two receptors are distinct, which is the basis for combining them.

The approval belongs to Tesamorelin alone. There is no trial of the Tesamorelin + Ipamorelin combination, so the blend inherits Tesamorelin’s evidence only for Tesamorelin, and Ipamorelin remains an unapproved research peptide. This page is a research reference, not a protocol.

## Mechanism

Tesamorelin: GHRH-receptor agonism (stabilized against DPP-4) driving GH synthesis and release, with documented visceral-fat reduction. Ipamorelin: selective GHS-R1a agonism amplifying the GH pulse. Dual-pathway stimulation is studied for a larger pulse than either alone.

## Research areas

Studied in: Growth-hormone secretagogue research, Visceral adiposity, GH pulse amplification.

Guides on this site:

- [Weight Loss & Metabolic Health](https://americanpeptide.com/research-areas/weight-loss): Incretin and metabolic peptides studied for glycemic control and fat loss.
- [Growth Hormone & Body Composition](https://americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition.

## Key research

- Approved GHRH component — Tesamorelin is FDA-approved (as a single agent) for HIV-associated lipodystrophy, unusual among secretagogue-blend components.
- Two-receptor design — GHRH (Tesamorelin) plus GHS-R (Ipamorelin) stimulation studied for a larger GH pulse.
- Blend is unstudied — the combination itself has no dedicated trial; the approval covers Tesamorelin alone.
- Ipamorelin not approved — the secretagogue component is a research peptide.

## Storage, handling & synthesis

**Storage.** Store lyophilized, frozen, and protected from light; after reconstitution keep refrigerated and use within a short window. The longer GHRH analog is the more fragile component.

**Handling.** Reconstitute gently without vortexing. Read any certificate as two separate assays — identity, purity, and content for both the GHRH analog and the secretagogue — not one blended figure.

**Synthesis.** A physical mixture of two separately made peptides — Tesamorelin (a stabilized 44-residue GHRH analog) and Ipamorelin (a short pentapeptide secretagogue). Tesamorelin is the harder, longer synthesis of the two; the blend has no combined purity number, so a real certificate assays each peptide on its own and states the amount of each. Pooling a long and a short peptide in one solution also raises stability questions a single-peptide vial does not.

## FAQs

### What is Tesamorelin + Ipamorelin?

A pairing of an FDA-approved GHRH analog (Tesamorelin) with a selective GH secretagogue (Ipamorelin), combining two receptor pathways to raise growth hormone.

### Is the combination FDA-approved?

No. Tesamorelin alone is approved for HIV-associated lipodystrophy; the combination with Ipamorelin has not been studied or approved as a blend.

### How does it compare to CJC-1295 + Ipamorelin?

Same two-receptor logic, but the GHRH component here (Tesamorelin) is a clinically approved, trial-backed analog rather than a research GHRH peptide.

### Is it approved as a blend?

No — only Tesamorelin as a single agent. This page is a research and educational reference.

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/tesamorelin-ipamorelin
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.